Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Duchenne muscular dystrophy (DMD) is a progressive muscle‐wasting disease caused by mutations in the dystrophin gene, which leads to structural instability of the dystrophin–glycoprotein‐complex with subsequent muscle degeneration. In addition, muscle inflammation has been implicated in disease progression and therapeutically addressed with glucocorticosteroids. These have numerous adverse effects. Treatment with human immunoglobulin G (IgG) improved clinical and para‐clinical parameters in the early disease phase in the well‐established <i>mdx </i> mouse model. The aim of the present study was to confirm the efficacy of IgG in a long‐term pre‐clinical study in <i>mdx </i> mice. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>IgG (2 g/kg body weight) or NaCl solution as control was administered monthly over 18 months by intraperitoneal injection in <i>mdx </i> mice beginning at 3 weeks of age. Several clinical outcome measures including endurance, muscle strength, and echocardiography were assessed. After 18 months, the animals were sacrificed, blood was collected for analysis, and muscle samples were obtained for <i>ex vivo </i> muscle contraction tests, quantitative PCR, and histology. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>IgG significantly improved the daily voluntary running performance (1.9 m more total daily running distance, <i>P </i> < 0.0001) and slowed the decrease in grip strength by 0.1 mN, (<i>P </i> = 0.018). IgG reduced fatigability of the diaphragm (improved ratio to maximum force by 0.09 ± 0.04, <i>P </i> = 0.044), but specific tetanic force remained unchanged in the <i>ex vivo </i> muscle contraction test. Cardiac function was significantly better after IgG, especially fractional area shortening (<i>P </i> = 0.012). These results were accompanied by a reduction in cardiac fibrosis and the infiltration of T cells (<i>P </i> = 0.0002) and macrophages (<i>P </i> = 0.0027). In addition, treatment with IgG resulted in a significant reduction of the infiltration of T cells (<i>P </i> ≤ 0.036) in the diaphragm, gastrocnemius, quadriceps, and a similar trend in tibialis anterior and macrophages (<i>P </i> ≤ 0.045) in gastrocnemius, quadriceps, tibialis anterior, and a similar trend in the diaphragm, as well as a decrease in myopathic changes as reflected by a reduced central nuclear index in the diaphragm, tibialis anterior, and quadriceps (<i>P </i> ≤ 0.002 in all). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>The present study underscores the importance of an inflammatory contribution to the disease progression of DMD. The data demonstrate the long‐term efficacy of IgG in the <i>mdx </i> mouse. IgG is well tolerated by humans and could preferentially complement gene therapy in DMD. The data call for a clinical trial with IgG in DMD. </p></section>

Therapeutic Benefit of Galectin-1: Beyond Membrane Repair, a Multifaceted Approach to LGMD2B

Treatment with galectin-1 improves myogenic potential and membrane repair in dysferlin-deficient models

Human laminin-111 and laminin-211 protein therapy prevents muscle disease progression in an immunodeficient mouse model of LAMA2-CMD

Inhibition of DNAJ-HSP70 interaction improves strength in muscular dystrophy

A role for Galgt1 in skeletal muscle regeneration

Altering the Modular Architecture of Galectins Affects its Binding with Synthetic α-Dystroglycan O-Mannosylated Core M1 Glycoconjugates In situ

Multipotent Stromal Cells Alleviate Inflammation, Neuropathology, and Symptoms Associated with Globoid Cell Leukodystrophy in the Twitcher Mouse

Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm

Galectin-3 Regulates Skeletal Muscle Loss Via TGFβ1-Smad2/3 Signaling Activation in Mice

Ribitol dose-dependently enhances matriglycan expression and improves muscle function with prolonged life span in limb girdle muscular dystrophy 2I mouse model

Base editing of the GLB1 gene is therapeutic in GM1 gangliosidosis patient-derived cells

Endogenous Galectin-3 is Required for Skeletal Muscle Repair

G.P.212

Linker Proteins Restore Basement Membrane and Correct LAMA2-related Muscular Dystrophy in Mice

Reduction of Tendon Fibrosis Using Galectin-3 Inhibitors

Bioengineered Model of Human LGMD2B Skeletal Muscle Reveals Roles of Intracellular Calcium Overload in Contractile and Metabolic Dysfunction in Dysferlinopathy

Identification of bazedoxifene for the treatment of LGMD R2 by high throughput screening

Improvement of Spontaneous Locomotor Activity in a Murine Model of Duchenne Muscular Dystrophy by N-Acetylglucosamine Alone and in Combination with Prednisolone

Long‐term human IgG treatment improves heart and muscle function in a mouse model of Duchenne muscular dystrophy

Soluble Heparin Binding Epidermal Growth Factor-Like Growth Factor Is a Regulator of GALGT2 Expression and GALGT2-Dependent Muscle and Neuromuscular Phenotypes

Nerve Pathology is Prevented by Linker Proteins in Mouse Models for LAMA2-related Muscular Dystrophy.